Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Graft add-on codes identify surgeons using biologics across spine and extremity cases. Main billing specialties: orthopedic surgery and neurosurgery.
Medicare fee-for-service bone graft & orthobiologics cases in the 40 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 12% on average (190 state-years, 2020–2024): read it as a direction with a margin.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 57 | 2,787−2.3%/yr | −2.3%/yr | 0.81.2× | 2% | 3,030 in 2030+1.4%/yr |
| Texas | 52 | 1,980−11%/yr | −11%/yr | 0.91.3× | 3% | 1,960 in 2030−0.1%/yr |
| Florida | 34 | 1,353−8.3%/yr | −8.3%/yr | 0.60.8× | 6% | 1,490 in 2030+1.6%/yr |
| Pennsylvania | 25 | 1,024−12%/yr | −12%/yr | 0.71.1× | 0% | 1,010 in 2030−0.2%/yr |
| Michigan | 27 | 796−14%/yr | −14%/yr | 0.91.3× | 3% | 740 in 2030−1.1%/yr |
| New York | 21 | 796−5%/yr | −5%/yr | 0.40.6× | 1% | 810 in 2030+0.2%/yr |
| Georgia | 15 | 773−3.8%/yr | −3.8%/yr | 0.91.3× | 5% | 720 in 2030−1.3%/yr |
| Illinois | 16 | 682−8.3%/yr | −8.3%/yr | 0.50.7× | 1% | 720 in 2030+0.9%/yr |
| Arizona | 19 | 661−4.1%/yr | −4.1%/yr | 0.91.3× | 2% | 740 in 2030+1.8%/yr |
| Ohio | 17 | 623−12%/yr | −12%/yr | 0.50.8× | 1% | 580 in 2030−1%/yr |
| Washington | 14 | 622−9.6%/yr | −9.6%/yr | 0.81.1× | 5% | 540 in 2030−2.4%/yr |
| Virginia | 17 | 601−14%/yr | −14%/yr | 0.60.8× | 0% | 650 in 2030+1.2%/yr |
| Massachusetts | 14 | 581−11%/yr | −11%/yr | 0.60.9× | 0% | 650 in 2030+1.9%/yr |
| North Carolina | 14 | 525−14%/yr | −14%/yr | 0.50.7× | 2% | 520 in 2030−0.2%/yr |
| Colorado | 10 | 513−4.9%/yr | −4.9%/yr | 1.01.5× | 3% | 590 in 2030+2.5%/yr |
| Tennessee | 16 | 498−9.2%/yr | −9.2%/yr | 0.71.0× | 3% | 450 in 2030−1.8%/yr |
| Arkansas | 8 | 484−8.7%/yr | −8.7%/yr | 1.21.8× | 2% | 370 in 2030−4.3%/yr |
| Maryland | 14 | 451−8%/yr | −8%/yr | 0.50.7× | 4% | 370 in 2030−3.3%/yr |
| South Carolina | 13 | 440−13%/yr | −13%/yr | 0.60.9× | 1% | 450 in 2030+0.5%/yr |
| Oregon | 9 | 416−2.9%/yr | −2.9%/yr | 1.01.4× | 3% | 440 in 2030+0.9%/yr |
| Indiana | 13 | 404−19%/yr | −19%/yr | 0.60.8× | 0% | 330 in 2030−3.2%/yr |
| Oklahoma | 13 | 397−18%/yr | −18%/yr | 0.81.2× | 1% | 430 in 2030+1.3%/yr |
| Minnesota | 6 | 371−9%/yr | −9%/yr | 0.81.1× | 0% | 410 in 2030+1.7%/yr |
| Louisiana | 8 | 369−1.6%/yr | −1.6%/yr | 0.91.3× | 1% | 360 in 2030−0.5%/yr |
| Missouri | 9 | 352−20%/yr | −20%/yr | 0.50.8× | 2% | 330 in 2030−1.3%/yr |
| Iowa | 8 | 349+3.2%/yr | +3.2%/yr | 0.81.1× | 0% | 470 in 2030+5.1%/yr |
| Delaware | 7 | 334−2.8%/yr | −2.8%/yr | 1.92.8× | 11% | 340 in 2030+0.5%/yr |
| Utah | 7 | 330−1.7%/yr | −1.7%/yr | 1.52.1× | 5% | 420 in 2030+4.1%/yr |
| Nebraska | 6 | 320−12%/yr | −12%/yr | 1.21.7× | 3% | 320 in 2030+0.2%/yr |
| Wisconsin | 4 | 304−9.5%/yr | −9.5%/yr | 0.50.8× | 1% | 360 in 2030+2.7%/yr |
| Alabama | 10 | 293−20%/yr | −20%/yr | 0.60.9× | 4% | 290 in 20300%/yr |
| Kansas | 6 | 241−8.6%/yr | −8.6%/yr | 0.60.8× | 0% | 210 in 2030−2.4%/yr |
| Connecticut | 5 | 234−7.1%/yr | −7.1%/yr | 0.71.0× | 0% | 240 in 2030+0.2%/yr |
| Kentucky | 7 | 228−18%/yr | −18%/yr | 0.50.7× | 0% | 260 in 2030+2.1%/yr |
| South Dakota | 5 | 198−11%/yr | −11%/yr | 1.52.2× | 0% | 210 in 2030+1.1%/yr |
| Nevada | 5 | 186−18%/yr | −18%/yr | 0.60.9× | 0% | 150 in 2030−3.1%/yr |
| New Jersey | 3 | 173−18%/yr | −18%/yr | 0.20.2× | 1% | 170 in 2030−0.7%/yr |
| Idaho | 4 | 149−11%/yr | −11%/yr | 0.71.0× | 1% | 200 in 2030+5.3%/yr |
| Mississippi | 5 | 119−17%/yr | −17%/yr | 0.30.4× | 11% | 90 in 2030−4.7%/yr |
| Wyoming | 2 | 118−11%/yr | −11%/yr | 1.11.6× | 0% | 110 in 2030−0.8%/yr |
Professional codes (what the surgeon bills): CPT 20930, 20931, 20936, 20937, 20938, 20939.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 221 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 59 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Medtronic | 69 |
| Kuros Biosciences | 12 |
| VB Spine | 9 |
| Orthofix | 8 |
| Baxter | 7 |
| Orthocon | 7 |
| Bone Solutions | 6 |
| Prosidyan | 6 |
| Anika Therapeutics | 5 |
| Surgentec | 5 |
| Biogennix | 4 |
| Collagen Matrix | 4 |
Product codes: MBP (filler, bone void, osteoinduction (w/o human growth factor)), MPW (filler, recombinant human bone morphogenetic protein, collagen scaffold, osteoinduction), MQV (filler, bone void, calcium compound), NEK (filler, recombinant human bone morphogenetic protein, collagen scaffold with metal prosthesis, osteoinduction). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 44% of the cases CMS names in California; 32 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 14,239 | 3,389,687−0.3%/yr | −0.3%/yr | 3,953,800 in 2030+2.6%/yr |
| Skin substitutes & wound grafts | 2,068 | 504,012+15%/yr | +15%/yr | 807,400 in 2030+8.2%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 24 companies reported engagement with surgeons in the covered states worth $6.3M in consulting, speaking, meals and travel tied to these products, about $11K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.